THE EFFECT OF TREATMENT WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ON THE CORRECTED QT INTERVAL IN PATIENTS WITH COVID-19

被引：0
作者：
Batemarco, Thomas [1 ]
Manongi, Ngoda [1 ]
Sunkaraneni, Sushant [1 ]
Vapnik, Joshua [1 ]
Kim, JoonHyuk [1 ]
机构：
[1] NewYork Presbyterian Queens, Flushing, NY USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2154 / 2154
页数：1
相关论文
共 50 条
  • [21] QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19
    Wu, Tan Chen
    Sacilotto, Luciana
    da Costa Darrieux, Francisco Carlos
    Pisani, Cristiano Faria
    de Melo, Sissy Lara
    Hachul, Denise Tessariol
    Scanavacca, Mauricio
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 114 (06) : 1061 - 1066
  • [22] Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection
    Saleh, Moussa
    Gabriels, James
    Chang, David
    Kim, Beom Soo
    Mansoor, Amtul
    Mahmood, Eitezaz
    Makker, Parth
    Ismail, Haisam
    Goldner, Bruce
    Willner, Jonathan
    Beldner, Stuart
    Mitra, Raman
    John, Roy
    Chinitz, Jason
    Skipitaris, Nicholas
    Mountantonakis, Stavros
    Epstein, Laurence M.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2020, 13 (06) : E008662
  • [23] Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
    Arshad, Samia
    Kilgore, Paul
    Chaudhry, Zohra S.
    Jacobsen, Gordon
    Wang, Dee Dee
    Huitsing, Kylie
    Brar, Indira
    Alangaden, George J.
    Ramesh, Mayur S.
    McKinnon, John E.
    O'Neill, William
    Zervos, Marcus
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 396 - 403
  • [24] Prevalence, Outcomes, and Predictors of Prolonged Corrected QT Interval in Hydroxychloroquine-Naive Hospitalized COVID-19 Patients
    Gupta, Praveen
    Gupta, Anunay
    Gupta, Kapil
    Bansal, Sandeep
    Sharma, Monica
    Balakrishnan, Ira
    CARDIOVASCULAR TOXICOLOGY, 2024, 24 (10) : 1053 - 1066
  • [25] The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel Coronavirus disease 2019
    Murat, Bektas
    Akgun, Hakan
    Akarsu, Muhittin
    Ozmen, Ahmet
    Murat, Selda
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2021, 67 (07): : 979 - 984
  • [26] Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
    Russo, Vincenzo
    Carbone, Andreina
    Mottola, Filiberto Fausto
    Mocerino, Rosa
    Verde, Raffaele
    Attena, Emilio
    Verde, Nicoletta
    Di Micco, Pierpaolo
    Nunziata, Luigi
    Santelli, Francesco
    Nigro, Gerardo
    Severino, Sergio
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [27] Reply to: "QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights"
    Hummel, James P.
    Akar, Joseph G.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (10) : 2795 - 2795
  • [28] Prolongation of QT interval due to hydroxychloroquine overdose used in COVID-19 treatment
    Aksel, Gokhan
    Islam, MehmetMuzaffer
    Aslan, Tuncay
    Eroglu, SerkanEmre
    TURKISH JOURNAL OF EMERGENCY MEDICINE, 2020, 20 (03): : 149 - 151
  • [29] Hydroxychloroquine versus hydroxychloroquine-azithromycin combination therapy on QT interval prolongation of COVID-19 patients: a systematic review and meta-analysis
    Pinandito, Yohanes Krisnantyo Adi
    Salfi, Qorina Nadya
    Putri, Kezia Warokka
    Caesario, Jefferson
    Rahmadi, I. Gusti Hanif
    Suhargo, Melisa
    Rafikasari, Aulia
    Julario, Rerdin
    Prajitno, Subur
    COR ET VASA, 2021, 63 (04) : 475 - 480
  • [30] Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
    Gautret, Philippe
    Honore, Stephane
    Lagier, Jean-Christophe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
12345